Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
benzodiazepine
recreational drug |
| gptkbp:ATCCode |
N05BA08
|
| gptkbp:brand |
Lectopam
Lexotan Lexotanil |
| gptkbp:CASNumber |
1812-30-2
|
| gptkbp:category |
sedative
muscle relaxant hypnotic GABAA receptor positive allosteric modulator |
| gptkbp:chemicalFormula |
C14H10BrN3O
|
| gptkbp:color |
white to off-white
|
| gptkbp:contraindication |
gptkb:myasthenia_gravis
severe respiratory insufficiency sleep apnea syndrome severe hepatic insufficiency |
| gptkbp:discoveredBy |
gptkb:Roche
|
| gptkbp:eliminationHalfLife |
10-20 hours
|
| gptkbp:excretion |
renal
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bromazepam
|
| gptkbp:indication |
anxiety disorders
short-term relief of severe anxiety |
| gptkbp:introducedIn |
1963
|
| gptkbp:IUPACName |
7-bromo-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
positive allosteric modulator of GABA-A receptor
|
| gptkbp:meltingPoint |
237–238 °C
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:pregnancyCategory |
gptkb:D_(Australia)
D (US) |
| gptkbp:PubChem_CID |
gptkb:CHEMBL1082
2348 2442 |
| gptkbp:riskFactor |
dependence
abuse potential withdrawal symptoms |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
muscle relaxation
drowsiness sedation ataxia impaired coordination memory impairment |
| gptkbp:solubility |
slightly soluble in water
|
| gptkbp:synonym |
Bromazepamum
Bromazepan |
| gptkbp:UNII |
5MG3P0FD8H
|
| gptkbp:bfsParent |
gptkb:N05BA
|
| gptkbp:bfsLayer |
7
|